CONTRADICTING EVIDENCE: Dynamics of ALK rearrangement and resistance mutations during TKI therapy...Emergence of at least one ALK mutation coincided with progressive disease in eight of these patients (Supplementary Table 2), while seven patients (ALK_06, 13, 18, 20, 25, 44, 62) showed increasing EML4-ALK fusion abundance upon progression on independent therapy lines (Supplementary Fig. 1).

...81 included patients had driver gene mutations, including 69 EGFR mutation (85.2%), 28 classical exon 19 deletions (34.6%), 17 exon 21 mutations (21%). In addition, there were nine ALK mutations (11.1%), one ROS (1.2%), and two HER2 mutation (2.5%)....The median progression-free survival of involved 81 patients was 13.87 months (95% confidence interval (CI): 11.66–16.08), and the median survival was 41.47 months (95%CI: 20.11–62.83)....TKIs are a viable option for mutant stage III unresectable NSCLC patients who have achieved good clinical benefit from TKI....